rna
interfer
rnai
pathway
lead
specif
degrad
complementari
target
mrna
basepair
recognit
virus
studi
shown
replic
cultur
cell
target
inhibit
synthet
sirna
rel
eas
sirna
design
versatil
rnai
target
broad
spectrum
mrna
led
promis
drug
discoveri
rnai
pathway
could
effect
pathogen
review
discuss
current
experiment
principl
guid
applic
rnai
hiv
describ
challeng
limit
need
surmount
order
sirna
becom
practic
antivir
drug
practic
use
rnai
therapi
hiv
infect
depend
overcom
sever
challeng
includ
abil
establish
longterm
express
sirna
without
offtarget
effect
capac
counteract
mutant
escap
virus
rna
interfer
rnai
emerg
common
vitro
sirna
duplex
load
onto
risc
serv
guid
strand
second
strand
passeng
rna
degrad
risc
tool
silenc
gene
express
introduct
small
use
guid
rna
basepairingmedi
recognit
target
rna
duplex
nucleotid
cell
elicit
specif
messeng
rna
mrna
specif
hybrid
degrad
complementari
gene
sequenc
basepairachiev
piwi
domain
protein
within
risc
ing
thought
rnai
pathway
serv
part
complex
degrad
silenc
target
substrat
mrna
innat
immun
defens
eukaryot
invas
exogebecaus
sirna
easi
design
synthes
nou
nucleic
acid
henc
plant
drosophila
cell
sequenc
specif
silenc
mrna
small
infect
viru
rnai
respons
trigger
foreign
rna
potenti
repres
futur
class
antivir
drug
doublestrand
rna
dsrna
molecul
origin
viru
shown
recent
retrovirus
human
use
small
interf
rna
sirna
potenti
engag
rnai
pathway
mammalian
cell
rel
short
period
time
rnai
shown
earli
step
rnai
respons
enlist
rnase
iii
enzym
cultur
cell
efficaci
variou
virus
includ
call
dicer
bind
cleav
long
dsrna
small
duplex
respiratori
syncyti
viru
rsv
influenza
viru
nucleotid
term
small
interf
rna
sirna
polioviru
hepat
c
viru
hcv
hiv
varieti
dicersirna
complex
recogn
tran
activ
reof
sirna
also
report
effect
interrupt
spons
region
tar
rnabind
protein
trbp
protein
viral
infect
two
sirna
strategi
consid
activ
pkr
pact
two
cellular
dsrna
bind
protein
hiv
first
target
essenti
viral
gene
second
target
cellular
gene
requir
hiv
replic
tabl
multiprotein
entiti
shuttl
interact
argonaut
protein
effector
complex
rnato
date
hiv
sequenc
target
includ
induc
silenc
complex
risc
one
two
strand
structur
gag
gene
infect
factor
vif
nef
tat
rev
cellular
protein
involv
multivesicular
bodi
format
target
tumor
suscept
gene
also
call
vacuolar
proteinsort
protein
involv
endocyt
traffick
cellular
protein
use
replic
peptidylprolyl
isomeras
cyclophilin
ra
oncogen
famili
member
mani
exampl
point
instead
directli
introduc
sirna
duplex
cell
effect
transient
mani
case
rnai
express
use
dna
plasmid
express
short
hairpin
rna
shrna
recogn
cell
dicer
enzym
remov
hairpin
loop
shrna
molecul
process
sirna
counterpart
current
myriad
system
avail
express
shrna
eg
control
rna
polymeras
iii
promot
rna
polymeras
ii
cmv
promot
sever
vector
system
eg
adenovir
lentivir
vector
allow
longterm
silenc
even
nondivid
cell
notori
mutabl
viru
effect
antivir
drug
base
sequenc
hybrid
must
take
account
mutat
sequenc
easili
inde
escap
env
tar
rna
instanc
sequencespecif
sirna
nucleotid
mutat
exampl
da
et
al
silenc
viral
rna
transient
suppress
hiv
replicaobserv
sirna
target
nef
rapidli
elicit
emert
period
day
singl
round
infect
genc
sirnaresist
virus
point
mutat
nef
cultur
cell
achiev
howev
import
note
gene
altern
delet
sirna
recognit
site
virionassoci
genom
rna
infect
cell
apcan
also
allow
viru
evad
restrict
moreov
pear
resist
rnaimedi
degrad
findevid
undergo
nucleotid
substitut
ing
argu
goal
prevent
genesi
integr
induc
altern
rna
fold
thu
shield
previous
proviru
use
sirna
one
target
cellular
factor
target
sequenc
access
sirna
requir
earli
step
replic
rather
viral
minim
mutat
escap
hiv
one
strategi
sequenc
simultan
use
multipl
sirna
target
discret
sequenc
sirna
direct
sever
relev
cellular
factor
likelihood
singl
viral
rna
molecul
would
mutat
target
sequenc
becom
increasingli
small
number
inde
test
antivir
efficaci
includ
sirna
target
escal
multitarget
strategi
aid
target
comput
model
predict
might
viral
entri
eg
sirna
hiv
coreceptor
chemokin
evolv
cell
express
multipl
antivir
sirna
report
addit
evolv
sirnaescap
mutat
virus
target
effect
aris
nucleotid
fortuit
also
encod
suppressor
factor
attenu
cell
rnai
basepair
sirna
mrna
consid
way
respons
much
remain
elucid
apa
particular
sirna
could
potenti
suppress
express
pear
multifacet
way
suppress
cell
rnai
intend
target
sever
unintend
mrna
offtarget
machineri
viral
tat
protein
appear
work
protein
phenomenon
signific
drawback
sirna
suppressor
rnai
addit
viral
rna
tar
also
envis
vivo
use
human
drug
one
anticip
use
suppressor
rnai
sirnabas
method
modif
minim
offtarget
hybrid
therapi
virus
use
contempl
would
need
greatli
improv
enabl
sirna
drug
one
need
consid
strategi
address
virusencod
rnai
develop
suppressor
despit
viral
encod
suppressor
ampl
anoth
unwelcom
advers
effect
sirna
use
potenevid
rnaimedi
inhibit
replic
tial
inappropri
elicit
interferon
inflammatori
possibl
suppressor
either
synthes
late
cytokin
normal
rna
duplex
shorter
nucleotid
amount
small
counter
effect
preexist
sirna
length
would
expect
trigger
interferonlink
shrna
protein
kinas
r
pathway
howev
recent
found
gurich
sequenc
tolllik
receptor
tlr
immunostimu
latori
motif
trigger
interferon
respons
even
present
duplex
shorter
nucleotid
minim
sirna
machineri
use
eukaryot
cell
nonspecif
interferon
respons
judici
care
must
exercis
use
process
class
endogen
small
rna
call
sequenc
design
sirna
drug
microrna
mirna
mirna
import
regul
least
cellular
gene
includ
involv
develop
signal
transduct
apoptosi
cell
prolifer
develop
antivir
sirna
drug
strategi
tumorigenesi
date
human
mirna
deand
limit
scribe
like
discov
see
mirna
databas
recent
optim
regard
possibl
sirna
drug
mechan
mirna
action
relev
aris
studi
indic
intraven
inject
mirna
infect
review
elsewher
sirna
direct
fa
protect
mice
liver
injuri
elabor
need
emphafibrosi
two
model
autoimmun
hepat
findsiz
fact
share
factor
shrna
sirna
ing
intranas
administr
separ
sirna
protect
mirna
process
satur
entiti
mirna
mice
rsv
infect
rhesu
macaqu
sar
essenti
cellular
metabol
viabil
machineri
coronaviru
infect
sirna
applic
mous
genit
mirna
genesi
divert
handl
exogen
sirna
tract
also
found
protect
lethal
herp
shrna
dearth
mirna
potenti
manifest
simplex
viru
type
infect
preliminari
posit
findcellular
toxic
hitherto
unexpect
find
inde
ing
prompt
phase
studi
initi
human
demonstr
recent
studi
vivo
overexpress
shrna
date
three
clinic
trial
complet
human
show
mice
studi
sever
liver
toxic
death
signific
sirna
toxic
sirna
current
clinic
mice
occur
within
week
shrna
treatment
explanainvestig
two
diseas
agerel
macular
degener
tion
fatal
satur
shrna
pathway
amd
caus
overexpress
vascular
endotheli
normal
use
liver
process
mirna
henc
high
growth
factor
vegf
respiratori
infect
caus
shrna
express
mous
liver
overwhelm
export
rsv
pathway
ie
need
transport
precursor
mirna
time
sirna
drug
outlin
nucleu
cytoplasm
interrupt
proper
sever
issu
uniqu
target
viral
transport
mirna
precursor
led
reduc
level
matur
gene
appli
target
cellular
gene
mirna
result
cellular
toxic
howev
question
relev
sirna
applic
apart
problem
pathway
satur
offtarget
efhow
best
deliv
sirna
virusinfect
cell
regard
fect
sirna
rais
addit
concern
ontarget
effect
emasever
method
consid
exampl
hcv
nate
perfect
complementar
guiderna
target
infect
procedur
coupl
sirna
cholesterol
almrna
ie
match
nucleotid
basepair
offlow
effici
target
hepatocyt
cell
preferenti
infect
viru
elsewher
novel
strategi
use
antibodysett
shown
effect
inhibit
hiv
replicamedi
sirna
deliveri
propos
tion
doxycyclinedepend
lentivector
go
forcel
whether
biochem
deliveri
techniqu
disward
major
challeng
perfect
vector
wholli
silent
tribut
sirna
effect
vivo
compart
await
shrna
express
unless
specif
trigger
verif
infect
also
virusbas
approach
deliv
shrna
howdespit
optim
deliveri
sirna
shrna
cell
ever
type
gene
therapi
approach
rais
issu
relat
abil
virus
mutat
escap
rnai
biosafeti
major
focu
cell
significantli
daunt
problem
multimod
approach
may
use
lentivir
vector
abil
infect
nondividhav
adopt
order
minim
viral
escap
ing
cell
rest
tcell
macrophag
progenitor
exampl
shrna
target
rev
use
time
hematopoiet
cell
cell
ogi
propos
therapi
strategi
